Pharmaceutical In a second piece of good news within a couple of days for German drug major Bayer (BAYN: DE), the European Commission has approved Stivarga (regorafenib) tablets for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have previously been treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine based chemotherapy, an anti VEGF therapy and an anti EGFR therapy. 30 August 2013